If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Philip Morris seals deal for UK's Vectura despite health group concerns

Thu, 16th Sep 2021 07:33

* Holders of roughly 75% Vectura shares tender support

* PMI needed 50% backing for deal to go through

* Extends deadline for other holders to tender shares by
Sept. 30
(Adds comment from health group; background on deal)

By Pushkala Aripaka and Siddharth Cavale

Sept 16 (Reuters) - Cigarette maker Philip Morris (PMI)
clinched its 1.1 billion-pound takeover of asthma inhaler
maker Vectura on Thursday, winning the support of the
British company's shareholders despite the concerns of health
professionals.

Vectura's shareholders decided to take the 165
pence-per-share offer from PMI, with nearly 75% backing the
deal.

Buying the London-listed inhaler maker is part of Philip
Morris' long term plan to develop "smoke-free" products and
switch to being a "broader healthcare and wellness" company.

But it has angered health groups such as Asthma UK and the
British Lung Foundation that have questioned whether a tobacco
group should own a company that cures the very respiratory
illnesses cigarettes cause.

PMI Chief Executive Jacek Olczak has argued that acquiring
Vectura is a critical part of his strategy to move the company
"Beyond Nicotine".

He told the Telegraph last month that opponents of the deal
were "not interested in progress" and accused them of "settling
old scores" with the tobacco industry.

Olczak said on Thursday PMI would provide Vectura's
scientists with the resources and expertise to reach its goal of
generating at least $1 billion in net revenue from "Beyond
Nicotine" products by 2025.

In the meantime, Asthma UK and the British Lung Foundation
said they have sent a letter urging the government to look into
any conflict of interest issues.

The letter was co-signed by 35 charities, public health
experts and clinicians.

"There's now a very real risk that Vectura's deal with big
tobacco will lead to the cigarette industry wielding undue
influence on UK health policy," said Sarah Woolnough, Chief
Executive of Asthma UK and the British Lung Foundation.

"We call on the government to stand by its commitment to the
World Health Organization Framework Convention on Tobacco
Control to prevent this happening," Woolnough added.

PMI has received regulatory clearances for the deal and
following the public tender process, its offer cannot now be
withdrawn.

While the company received the 50% threshold to make its
offer unconditional, it has not yet reached the 75% of shares it
needs to delist Vectura.

PMI said it was extending its offer to Sept 30., to give
Vectura shareholders time to accept its proposal.

"Phillip Morris isn't ignoring the elephant; it's making us
all take a long hard look. Discomfort is good, it tends to
deliver change, but care must be taken that the promised change
does come and there are no detours on the journey," AJ Bell
financial analyst Danni Hewson said.
($1 = 0.7234 pounds)
(Reporting by Pushkala Aripaka and Siddharth Cavale in
Bengaluru;Editing by Elaine Hardcastle)

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.